BioHarvest Sciences (BHST) Competitors $9.60 +0.28 (+3.00%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock BHST vs. OPT, XNCR, SEPN, BCYC, KURA, MRVI, ORKA, PRME, UPXI, and TERNShould you be buying BioHarvest Sciences stock or one of its competitors? The main competitors of BioHarvest Sciences include Opthea (OPT), Xencor (XNCR), Septerna (SEPN), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Maravai LifeSciences (MRVI), Oruka Therapeutics (ORKA), Prime Medicine (PRME), Upexi (UPXI), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. BioHarvest Sciences vs. Its Competitors Opthea Xencor Septerna Bicycle Therapeutics Kura Oncology Maravai LifeSciences Oruka Therapeutics Prime Medicine Upexi Terns Pharmaceuticals Opthea (NASDAQ:OPT) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Does the media favor OPT or BHST? In the previous week, BioHarvest Sciences had 18 more articles in the media than Opthea. MarketBeat recorded 20 mentions for BioHarvest Sciences and 2 mentions for Opthea. Opthea's average media sentiment score of 1.66 beat BioHarvest Sciences' score of 0.01 indicating that Opthea is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opthea 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioHarvest Sciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is OPT or BHST more profitable? Opthea has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -39.95%. Opthea's return on equity of 0.00% beat BioHarvest Sciences' return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A BioHarvest Sciences -39.95%-11,357.84%-39.94% Which has stronger valuation and earnings, OPT or BHST? BioHarvest Sciences has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$120K4,373.61-$220.24MN/AN/ABioHarvest Sciences$25.19M6.26-$12.91M-$0.70-13.71 Which has more volatility & risk, OPT or BHST? Opthea has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Do analysts prefer OPT or BHST? Opthea presently has a consensus price target of $1.33, indicating a potential downside of 60.90%. BioHarvest Sciences has a consensus price target of $13.67, indicating a potential upside of 42.36%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts plainly believe BioHarvest Sciences is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in OPT or BHST? 56.0% of Opthea shares are owned by institutional investors. 3.2% of Opthea shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryOpthea beats BioHarvest Sciences on 9 of the 15 factors compared between the two stocks. Get BioHarvest Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for BHST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHST vs. The Competition Export to ExcelMetricBioHarvest SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.63M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-13.7120.7630.8625.25Price / Sales6.26231.85403.9088.50Price / CashN/A41.5625.2228.45Price / Book120.009.759.516.00Net Income-$12.91M-$54.74M$3.26B$265.34M7 Day Performance8.84%8.09%4.49%2.81%1 Month Performance38.73%7.70%5.18%1.50%1 Year PerformanceN/A18.13%31.98%25.46% BioHarvest Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHSTBioHarvest SciencesN/A$9.60+3.0%$13.67+42.4%N/A$157.63M$25.19M-13.71N/AEarnings ReportAnalyst RevisionGap UpOPTOpthea0.4022 of 5 stars$3.41+7.2%$1.33-60.9%N/A$524.84M$120K0.008Gap UpHigh Trading VolumeXNCRXencor3.7245 of 5 stars$7.23-1.2%$26.43+265.5%-52.7%$522.09M$110.49M-3.01280SEPNSepterna1.7088 of 5 stars$11.69-0.1%$26.75+128.8%N/A$521.33M$1.08M0.00N/ANews CoverageEarnings ReportUpcoming EarningsAnalyst DowngradeBCYCBicycle Therapeutics2.9078 of 5 stars$7.65+2.5%$21.25+177.8%-66.8%$516.63M$35.28M-2.44240Short Interest ↓KURAKura Oncology4.089 of 5 stars$5.54-7.0%$24.50+342.2%-61.9%$515.98M$53.88M-2.45130News CoverageAnalyst UpgradeHigh Trading VolumeMRVIMaravai LifeSciences3.6998 of 5 stars$2.20+8.4%$6.64+201.8%-73.0%$515.69M$259.18M-1.93610ORKAOruka Therapeutics2.7167 of 5 stars$13.09-4.2%$40.38+208.4%N/A$511.81MN/A-2.90N/ANews CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionPRMEPrime Medicine3.5681 of 5 stars$3.79+3.0%$8.92+135.3%-15.8%$509.74M$3.85M-1.85234UPXIUpexi2.5404 of 5 stars$6.04+8.4%$15.50+156.6%+84.3%$497.74M$26M0.00130Short Interest ↑TERNTerns Pharmaceuticals3.9096 of 5 stars$6.08+7.8%$15.63+157.0%-2.8%$493.56MN/A-5.8540 Related Companies and Tools Related Companies Opthea Competitors Xencor Competitors Septerna Competitors Bicycle Therapeutics Competitors Kura Oncology Competitors Maravai LifeSciences Competitors Oruka Therapeutics Competitors Prime Medicine Competitors Upexi Competitors Terns Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BHST) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioHarvest Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioHarvest Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access